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The purpose of this Doctor of Nursing Practice capstone project was to evaluate a 
structured rural smoking cessation program that integrated electric cigarettes as an 
additional option to other standard interventions.  The aims of the program evaluation 
were to develop an evaluation design  and methodology to guide data collection and 
analysis, analize findings, and provide recommendations regarding the current program 
and future usage or changes.  
The Donabedian and bridge evaluation models provided the framework to 
evaluate the smoking cessation program, make recommendations for future applications, 
potential improvements, and determine elements of the program that should be continued 
in its current state.   
After obtaining Institutional Review Board approval, 44 participants were 
recruited to participate in the smoking cessation program evaluation.  The results 
indicated 14 (32%) quit smoking and seven (16%) switched to e-cigarettes.  Of the 
remaining 23 participants, 13 (30%) successfully cut down to less than half of their 
starting tobacco use level with the use of e-cigarettes.  Of the 14 participants who quit, 10 
used e-cigarettes exclusively and the other four also used Bupropion (two) or Chantix 
(two).  Of the seven who switched to e-cigarettes, three used only e-cigarettes and four 
used e-cigarettes and Bupropion.  Of the 13 participants who cut down to less than half of 
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their starting amount of tobacco cigarettes, seven were only using e-cigarettes and six 
were using e-cigarettes and Bupropion.  Program participants’ success rate at cessation or 
switching to e-cigarettes exclusively was double both the national and state averages of 
21-24%, resulting in a significant harm reduction for patients and families. 
Recommendations from the evaluation included continuing the program with 
modifications to educational materials and follow up strategies, using different types of 
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STATEMENT OF THE PROBLEM 
 
 
Background and Significance 
Tobacco use remains the leading preventable cause of death, disease, and 
disability in the United States (National Institute on Drug Abuse [NIDA], 2010).  A 2012 
report from the Center for Disease Control and Prevention (CDC) indicated that the 
adverse effects related to smoking account for an estimated 443,000 deaths (or nearly one 
in five deaths) each year in the United States.  Exposure to secondhand smoke can also 
cause death and diseases (NIDA, 2010).  Every year 126,000 Americans are exposed to 
secondhand smoke and almost 50,000 nonsmokers die from diseases related to 
secondhand smoke annually.  A 2009 Morbidity and Mortality report (CDC, “Morbidity 
and Mortality Report”) indicated that in 2008, an estimated 20.6% (46 million) adults in 
the United States were current cigarette smokers; among those, 45.3% (20.8 million) had 
stopped smoking for one day or more during the preceding 12 months in an attempt to 
quit.   
Smoking cessation is challenging and frequently requires multiple attempts before 
an individual is able to quit.  Switching from tobacco cigarettes to a nicotine replacement 
therapy (NRT) is standard practice in smoking cessation programs.  However, most 
smokers do not find the current NRT products to be as satisfying as cigarettes as they 
provide nicotine at doses and rates of delivery that are a poor substitutes for cigarettes  
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(Houezec, McNeill, & Britton, 2011).  There is a promising new smoking cessation aide 
on the market called electronic cigarettes (e-cigarettes).  An e-cigarette is an electrical 
device that attempts to simulate the act of smoking a tobacco cigarette.  Most of them are 
composed of a rechargeable, battery-operated heating element, a replaceable or refillable 
cartridge, and an atomizer that converts the contents in the cartridge to vapor that is 
inhaled by the user.  Multiple choices for the strength of nicotine in the liquid or the 
cartridges range from placebo to full strength (24 mg) and are also available in multiple 
flavors.  The e-cigarette alleviates the health risks related to second hand smoke and 
promises to be far more effective at increasing the success rate of tobacco cessation. 
Problem Statement 
 Primary care providers in a rural northern Colorado region noted that in their 
community-based practice, smoking rates and related health problems were higher than 
both the state and national averages (CDC, 2012).  After the realization that there were 
very few available resources to assist local residents with smoking cessation, a program 
was developed and implemented in a selected rural primary care setting that offered the 
e-cigarette as an alternative means of NRT or harm reduction.  The e-cigarette was 
chosen as the alternative method in response to the poor success rate and potential 
adverse side effects of the current approved smoking cessation options.  For a smoker, the 
health risks of continuing to smoke tobacco cigarettes far outweigh the risks of any NRT 
they might choose including e-cigarettes (Cobb, Byron, Abrams, & Shields, 2010; 
Tobacco Vapor Cigarette Association [TVECA], 2010).  Although the smoking cessation 
program was developed with implementation goals and objectives, no systemic formal 
evaluation plan was included.  This capstone project was initiated to create and perform 
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an evaluation plan for the smoking cessation program and to make recommendations for 
current and future participants in this program. 
Purpose 
The purpose of this DNP capstone project was to evaluate a structured smoking 
cessation program that integrated e-cigarettes as an additional option to other standard 
interventions.  The aims of the program evaluation were to develop an evaluation design  
and methodology to guide data collection and analysis, analyze findings, and provide 
recommendations regarding the current program and future usage and/or changes.  
Theoretical Frameworks 
  The Donabedian (1972) model and the bridge evaluation model (Sieloff, 1999) 
were used to evaluate the program and provided the basis for this capstone project.  These 
two models served as the foundation for the evaluation plan to define and describe 
objectives, describe and measure indicators of success, and utilize outcome 
measurements.  The Donabedian and bridge models provided the framework to evaluate 
the program, make recommendations for future applications and potential improvements, 
and determine elements of the program that should be continued in their current state.   
Donabedian Model 
The literature review of the Donabedian model revealed its use in multiple 
program evaluations.  According to Donabedian (1972), the definition of evaluation is  
the use of scientific method and rigorous and systemic collection of research data 
to assess the effectiveness of organizations, services and programs in achieving 
predefined objectives  For health services, it is used to see if they fulfill their 
stated goals, targets or objectives. (p. 103) 
   
It is based on the collection of data about the structure, process, and outcomes of the 
service as well as the appropriateness of the service (Donabedian, 1972).  Evaluations can 
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be formative or summative.  A formative evaluation involves the collection of data while 
the program is active--the goal is is to develop or improve the program.  A summative 
evaluation involves collecting data about an active or terminated program--the goal is to 
decide whether the program should be continued or repeated (Donabedian, 1972).   
Program evaluation is the systemic investigation of the worth or merit of a 
program.  A program evaluation can show evidence of acheivement of program goals, 
identify effective program components, determine why some program components are 
effective while others are not, identify potential program improvements, and provide 
information on a program’s cost effectiveness (Donabedian, 1972).  The first step in a 
program evaluation is to identify the purpose of the evaluation and develop evaluation 
questions based on program inputs (processes) and expected outcomes.  The next step is 
to develop an evaluation design  and methodology to guide data collection and analysis.  
This requires identification of the data necessary to answer evaluation questions, methods 
of data collection, sampling strategy, and data collection instruments (Donabedian, 1972).  
The data are then analyzed, findings are interpreted, and recommendations are made. 
The Donabedian model first originated in 1966 and has guided work regarding the 
elements used to evaluate and compare health care quality for over four decades 
(Donabedian, 1972; Mitchell, Ferketich, & Jennings, 1998).  Donabedian’s (1972) 
framework specifies that structure influences process, influences outcomes, and is easy to 
use for theory testing and organizing data.  For example, Donabedian’s model influenced 
the Quality Assessment/Quality Assurance Movement of the 1970s, the Total Quality 
Management Movement of the late 1980s, and more recent performance measurement 
initiatives (Larson & Muller, 2002/2003).  It was used to (a) evaluate patient satisfaction 
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for diabetic patients (Westaway, Rheeder, VanZyl, & Seagar, 2003); (b) evaluate how the 
structure and process affect the outcome in a nursing facility (Cook, 2002); (c) evaluate 
the structure of models serving adults with mental retardation/developmental disabilities 
(Pulcini & Howard, 1997); (d) apply the Donabedian model as the framework for 
bariatric surgery (Smitz Naranjo & Viswanatha Kaimal, 2011); (e) evaluate patient 
preception of nursing service quality (Kobayashi, Takemura, & Kanda, 2011); (f) review 
the quality of care in systemic lupus erythematosus patients (Lawson & Yazdany, 2012); 
and (g) assess patient satisfaction with quality of care in a large teaching hospital (Tasso 
et al., 2002) to mention just a few examples. 
The Donabedian (1972) structure-process-outcome model uses three criteria to 
evaluate a health care program: 
1.  Structure measures: Focus on conditions under which the care is provided 
and evaluates the inputs and resources into the services.  It is the 
organizational framework for the activities that happen within the health 
service. 
2. Process measures: Focus on what a health care provider does to maintain or 
improve patients’ health.  These are the activities themselves (i.e., screening, 
diagnosis, treatment, education).  
3. Outcome measures: Focus on changes in health status that are attributable to 
health care.  They refer to the effectiveness of activities that are measured 
by mortality and morbidity rates, complication rates, disability, quality of 




Bridge Evaluation Model 
The bridge evaluation model was first implemented in 1999 by Debra Sieloff  
(1999).  “The bridge symbolism represents the structure over open waters (the evaluation 
environment) that can transport the evaluation manager from the beginning of the 
evaluation (the question) to the end (finding the answer to the question)” (Sieloff, 1999, 
p. 14).  The bridge also serves to illustrate the flexibility of the model (like two-way 
traffic on a bridge): the evaluation manager can modify the evaluation plan, the data 
collection tools, use of data, reporting methods, and post evaluation evaluation systems 
much like a traveler can change directions on a bridge (Sieloff, 1999).  The bridge 
evaluation model could be used to “evaluate the worth or merit of any form of program, 
problem, service, product, or issue” (Sieloff, 1999, p. 15).  This model could be used to 
identify the judgement methods including defination of standards and collection of 
relevant data.  It could then be used to apply the standards to determine the value, quality, 
utility, effectiveness, or significance of the evaluation’s objective.  
Based on the work of Worthen, Sanders, and Fitzpatrick (1997), the bridge 
evaluation model illustrates the process and factors that determine the outcome of an 
evaluation.  This model illustrates the evaluation process and the following elements 
(Sieloff, 1999): 
1. Plan/design: Define the purpose, use, type, approach, resources, reporting 
methods, protocol, and schedule.   
2. Data collection: Include new and existing data.  Gather both qualitative and 
quantitative data using methods that will achieve the evaluation objective, 
are unbiased, and appropriate.  
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3. Testing and Assessing: Data, data resources, situational context, reliability, 
and accuracy.  Test validity, completeness, and correctness of data.  Look at 
such things as rival information, exceptions, varying perspectives from 
observers, discrepancies, reactions, and evaluator effects. 
4. Report the evaluation findings.  Include introduction, evaluation, 
conclusion, and recommendations that incorporate an assessment of the 
achievement of objectives, violation of any ethical or legal principles, 
alterations of original evaluation needs, value of the evaluation’s 
accomplishment, process and outcome of the data testing, expectations to 
identify performance levels, and results achieved via the evaluation system.  
5.  Evaluation: Test the usefulness or identify learning opportunities for future 
applications.  
The Donabedian (1972) and bridge evaluation models (Sieloff, 1999) provided 
the framework to evaluate the smoking cessation program, make recommendations for 
future applications, potential improvements, and determine elements of the program that 
should be continued in its current state.  These frameworks provided a concise, easy-to-
follow structure to identify the objectives, collect the data, evaluate the tools used to 
collect the data, evaluate whether the objectives were met, and provide recommendations 








PROJECT DESCRIPTION AND DESIGN 
 
 
Literature Review and Supporting Data Synthesis 
 
Tobacco Use and Smoking Cessation 
 
More deaths are caused by cigarette smoking each year than from all other causes 
including human immunodeficiency virus (HIV), alcohol and drug use, motor vehicle 
injuries, and murders and suicides combined.  The Centers for Disease Control and 
Prevention (CDC; 2011) reported that smoking causes an estimated 90% of all lung 
cancer deaths in men, 80% of lung cancer deaths in women, and an estimated 90% of all 
deaths related to chronic obstructive lung disease.  Smoking also increases the risk of 
coronary heart disease and stroke by two to four times compared to nonsmokers.  The 
report also indicated that cigarette smoking reduces circulation in the body by narrowing 
blood vessels and puts smokers at risk for developing peripheral vascular disease and 
abdominal aortic aneurysms.  Cigarette smoking causes multiple lung diseases including 
emphysemia, bronchitis, asthma exacerbations, and chronic airway obstruction, and is 
also associated with lower bone density and an increased risk of hip fractures  (CDC,  
2012).  In women, cigarette smoking has also been shown to increase infertility, preterm 
delivery, stillbirth, low birth weight, and sudden infant death syndrome (CDC, 2012).   
In the state of Colorado, the highest rate of smoking occurs in adults age 18-44.  
Smoking prevalence is the highest in adults with a high school education level or lower, 
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those living below the federal poverty level, and those with other substance abuse 
problems (CDC, 2009).  American Indians have the highest incidence of smoking at 
36.1%, followed by Caucasians at 16.5% (CDC, 2011).  
There are currently five different nicotine replacement therapies (NRT) approved 
for use by the Food and Drug Administration: nicotine chewing gum, transdermal 
patches, nasal sprays, inhalers, and lozenges.  All of the current NRTs have been shown 
to have similar efficacy and side effect profiles (Stead, Perera, Bullen, Mant, & 
Lancaster, 2008).  Prescription medications approved to help with tobacco cessation 
currently include bupropion (Zyban) and varenicline (Chantix).  Bupropion reduces the 
symptoms of nicotine withdrawal, is usually well tolerated, and can be taken with NRTs 
(American Cancer Society, 2011).  Varenicline is a newer prescription medication and 
works by interfering with nicotine receptors in the brain.  Varenicline can be very 
effective at helping with tobacco cessation but has multiple reported side effects: 
headaches, nausea, vomiting, trouble sleeping, unusual dreams, flatulence, changes in 
taste, depressed mood, changes in behavior, and thoughts of or attempted suicide  
(American Cancer Society, 2011).  It is also expensive with poor coverage on most 
prescription plans. 
According to the CDC in 2009, the success rate for an individual attempting to 
quit “cold turkey” was between 4% to 7%.  Any of the NRTs could double this number 
from 8% to 14%; Bupropion could increase the cessation rate by approximately 20% and 
Varenicline by approximately 33%.  The success rate with combination therapies is still 
only approximately 25% (CDC, 2009).  This means that three out of four smokers will 
still fail in their attempts to quit smoking.  Users most often relapse due to withdrawal 
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symptoms, stress, and weight gain.  Although nicotine is extremely addictive and can be 
toxic if ingested in large doses, it does not cause cancer.  The complex mixture of 
chemicals in tobacco is the known carcinogen.  There are over 7,000 chemicals in 
tobacco cigarettes and over 70 of them have been proven to be carcinogenic (CDC, 
2009).   
Electric Cigarettes 
E-cigarettes offer a novel approach to smoking cessation as they can be used long 
term, deliver a dose of nicotine that can be decreased gradually until at placebo level, are 
significantly cheaper than tobacco cigarettes, and mimic cigarette smoking activities so 
the smoker does not have to give up his or her behavior.  By using an e-cigarette instead 
of a tobacco cigarette, an individual can still ingest the same amount of nicotine but none 
of the 7,000 carcinogens found in tobacco cigarettes. 
An extensive literature review revealed a limited number of studies that 
specifically evaluated the use of e-cigarettes for smoking cessation.  The three studies 
that were found were double blind, randomized, and had no stockholder involvement 
(Cahn & Siegel, 2010; Eisenberg et al., 2008; Stead, Perera, Bulle, Mant, & Lancaster, 
2008).  No evidence was found indicating e-cigarettes caused or contributed to increased 
harm.  All of the available studies that did test the contents of e-cigarettes indicated they 
were much safer than tobacco cigarettes (Bullen, Thornley, Glover, Lin, & Laugensen, 
2010; Cahn & Siegel, 2010; Foy, Bombick, Doolittle, Mosberg, & Swauger, 2004; 
Laugesen, 2008; Meckley et al., 2004; Patskan & Reininghaus, 2003; Roethig, Kinser, 
Lau, & Wang, 2005; Stabbert et al., 2003; Terpstra et al., 2003; Tewes, Meisgen, Veltel, 
Roemer, & Patskan, 2003;Werley et al., 2008).  Most of the studies found no harmful 
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chemicals in e-cigarettes; the few that did find trace amounts of carbon monoxide and 
diethylene glycol were between a 500-fold to 1400-fold reduction in the concentration of 
that found in tobacco cigarettes (Cahn & Siegel, 2010).   
A report from the U.S. Food and Drug Administration (USFDA; 2010) tested two 
different e-cigarettes and found nicotine in both products and very low levels of tobacco- 
specific nitrosamines and impruities.   However, the report failed to present standard 
protocols for proper study design with regard to the testing of the control device (nicotrol 
inhaler), documenting the number of samples tested, and failed to present statistical 
analyses when quantifiable results were obtained.  The FDA stated the level of impurities 
found was not quantifiable and was below the limit of quantification (WebMD, 2011 ).   
A review of the consumer literature revealed approximately 90% of e-cigarette 
users were attempting to quit smoking and all had previously smoked tobacco cigarettes  
(All Electronic Cigarette Brands: Comparisons and Reviews, 2011; Etter, 2010).  An 
extensive literature review found no studies that actually used e-cigarettes as a smoking 
cessation aide in a structured smoking cessation program.  The significant gap in the 
literature indicates a need to further investigate this product which is currently on the 
market and being used by consumers.  This capstone project could prove to be a starting 
point to evaluate the efficacy of ecigarettes as a smoking cessation aide.  The literature 
did show there was extensive information and feedback on comsumer review sites that 
indicated e-cigarettes were used frequently and effectively as a smoking cessation aide  
(All Electronic Cigarette Brands, 2011).  
The greatest concerns and complaints from consumer reviews were the variations 
in the dosage of nicotine delivered, technical/mechanical defects or failure of the e-
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cigarettes, and lost effectiveness toward the end of use of the cartridge (All Electronic 
Cigarette Brands, 2011).  Over 40 brands of e-cigarettes were identified; the starter kits 
ranged in price from $30 to $200 (see Table 1).  The cost of the nicotine cartridges or 
liquid nicotine is $2.00 versus the average $5.00 for a pack of tobacco cigarettes (All 
Electronic Cigarette Brands, 2011).  After a thorough review of multiple brands of e-
cigarettes, the brands BluCigs (2012) and SmokeTip (2012) had the best consumer 
review ratings and were the e-cigarette brands recommended in this program.  Both 
brands scored at least a four out of five on five different areas: battery, vapor, service, 
cost/value, and overall from over 200 reviews.  Both brands are made in the United States 
and the nicotine cartridges are made from FDA approved ingredients.  The BluCig has a 
one year warranty and the SmokeTip has a lifetime warranty.  Both brands come in a 
variety of flavors and nicotine doses and both offer free shipping to anywhere in the 
United States (BluCigs, 2012; SmokeTip, 2012).  The cost analysis data indicated the 
only smoking cessation alternative cheaper than e-cigarettes was Bupropion.  As 
discussed earlier, Bupropion has a 24% success rate (CDC, 2009). 
The literature review supported the need for more rigorous research using double 
blind, randomized controlled trials and meta-analyis evaluating the safety and efficacy of 
e-cigarettes for use in tobacco cessation.  In addition, current research demonstrates the 
need for more systematic regulation of e-cigarette manufacturers regarding the technical 
quality of their products.  After a review of the evidence available thus far, it is apparent 
that e-cigarettes provide a greater benefit as an intervention for smoking cessation than a 
risk for added harm.  They show significant potential to increase the smoking cessation 
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Cost Analysis of Nicotine Replacement Therapy and Prescription Medications for 
Smoking Cessation 
 
Replacements Cost Per Day Cost Per Month 
Nicotine Patches Average $2.70-$4.70 each/ 
use 1 per day 
Average $81-$141 per month 
Nicotine  Gum Average $0.35-$0.63 each/ chew 
1 every 1-2 hours 
Average $126-$227 per month 
Nicotine Lozenges Average $0.49 each/ 
suck on one every 1-2 hours 
Average $177 per month 
Nicotine Oral Inhaler $7.80 per day $234 per month 
Nicotine Nasal Inhaler $6.66per day $200 per month 
Bupropion Oral Medication $0.90-$1.66 per day $27-$50 per month 
Varenicline Oral Medication $5.96-$6.4 per day $179-$192 per month 
BluCig $2.00 per day $60 per month 
SmokeTip $1.59 per day $47.70 per month 
Note. In store cost analysis done February 2012 at Walgreens and Walmart, Craig, Colorado.   
Information based on 1 pack per day/smoker. 
 
Description of the Kinder Family Clinic Smoking  
Cessation Program and Population 
Kinder Family Clinic is a rural physician-owned health care clinic that serves the 
residents of Moffat County and multiple surrounding areas of northwestern Colorado.  It 
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is one of few health care resources in the area and offers care to all ages for both acute 
and chronic problems.  Many of the acute and chronic problems are caused by or 
exacerbated by tobacco use.  The Kinder Family Clinic Smoking Cessation Program was 
implemented in response to the poor cessation rates related to current smoking cessation 
therapy options and offers an alternative therapy for smoking cessation as a means for 
harm reduction for those individuals who are not interested in quitting but would be 
willing to switch to e-cigarettes as an alternative to smoking regular tobacco cigarettes.  
This rural area is extremely limited regarding access to smoking cessation treatment and 
education.  The Kinder Family Clinic Smoking Cessation program was a six month 
program implemented on a trial basis and will be continued or changed based on this 
program evaluation.  The program included established patients who were current 
smokers who chose to participate.   
Theoretical Framework Used for the  
Smoking Cessation Program 
The transtheoretical model (TTM; Prochaska & DiClemente 1983; Prochaska, 
DiClemente, & Norcross, 1992; Prochaska, DiClemente, & Velicer, 1985) and the five 
stages of change originally developed by James Prochaska provided the foundation for 
the Kinder Family Clinic Smoking Cessation Program.  The TTM provided a structured 
evidence-based framework to assist in evaluating an individual’s readiness to quit 
smoking and support for the smoking cessation process (Woody, DeCristofaro, & 
Carlton, 2008).  The stages of change described in the model represent a time period as 
well as a set of tasks needed to move from one stage to the next.  There are five stages of 
change; for each stage, different change processes and relational stances provide optimal 
progress.  Individuals typically recycle through these five stages an average of three to 
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four times before they actually overcome their addiction (Prochaska, 1992; Prochaska & 
DiClemente, 1983; Prochaska et al., 1985; Prochaska, Velicer, DiClemente, & Fava, 
1988).  The five stages included the following:  
1. Precontemplation: The individual has no intention to change their behavior.  
Individuals in this stage are unaware or under-aware that they have a 
problem.  However, family, friends, and employers are well aware that the 
patient has a problem. 
2. Contemplation: The individual has some intention to change but no 
behavior.  Individuals in this stage are aware that they have a problem, are 
seriously thinking about overcoming it, but have made no effort or 
commitment to change.  Many individuals in this stage struggle with 
positive evaluations of their dysfunctional behavior and the amount of 
effort, energy, and loss they feel to overcome their problem. They may 
remain stuck in this stage for a long period of time. 
3. Preparation: The individual intends to change and early inconsistent 
behavioral attempts to change are made.  Individuals in this stage have made 
some reduction in their problem behavior, intend to take action within the 
next month, but have not yet reached the point for effective action.  
4. Action: The individual has consistent behavioral performance for less than 
six months.  This is the stage where an individual is modifying their 
behavior to overcome the problem.  The action stage requires considerable 
commitment of effort and energy to change the behavior.  An individual is 
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classified in this stage if they have quit their behavior for a period from one 
day to six months.  
5. Maintenance: The individual has had consistent behavioral performance for 
at least six months.  This is the stage where the individual must work to 
prevent a relapse and is consistently engaging in a new positive, 
incompatible behavior.  This period extends from six months to an 
indeterminate period (Prochaska 1992; Prochaska & DiClemente, 1983; 
Prochaska et al., 1985, 1988).  
The majority of addicted individuals are not in the action stage (Prochaska 1992; 
Prochaska & DiClemente, 1983; Prochaska et al., 1985, 1988).  Only 10-15% of smokers 
are prepared for action, approximately 30-40% are in the contemplation stage, and 50-
60% are still in the precontemplation stage.  The amount of progress an individual makes 
during treatment tends to be a function of their pre-treatment stage.  To treat all smokers 
as if they are all in the same stage is naïve, yet that has been the approach used in most 
traditional treatment programs (Prochaska et al., 1992).  Treatment programs designed to 
help individuals progress just one stage in a month can double their chances of taking 
action on their own (Prochaska et al., 1992).  Relapes are almost inevitable and are part 
of the process of working toward life-long change (Zimmerman, Olsen, & Bosworth, 
2000).  Effective treatment programs need to assess an individual’s stage of readiness for 
change and tailor interventions accordingly (Prochaska et al., 1992).   
The concepts of addiction were used as a secondary framework for this smoking 
cessation program.  Nicotine addiction is the most common form of chemical dependence 
in the United States (American Society of Addiction Medicine, 2008).  Addiction is 
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important to take into account when designing smoking cessation interventions as 
withdrawal symptoms impede quitting (Andersen, 2007).  Avoiding withdrawal 
symptoms is the number one reason why individuals fail in their attempt at smoking 
cessation (Andersen, 2007).  Nicotine replacement therapy is an effective way to deal 
with the physiological addiction to tobacco as it prevents nicotine withdrawal symptoms 
(Andersen, 2007).   
Smoking Cessation Program Objectives 
The main objective of this program was to offer a new smoking cessation option 
that could dramatically improve the overall smoking cessation rate of all populations.  
The second objective was to provide an alternative to tobacco cigarettes for those 
individuals not interested in quitting smoking but willing to switch to a much safer and 
cheaper alternative.  
Implementation Methods and Tools Used for Program 
Participant Recruitment 
 The goal was to recruit patients from Kinder Family Clinic Practice and the 
surrounding community who were willing to participate in the program.  The objectives 
were as follows: 
1. Identify Kinder Family Clinic patients who are current smokers using the 
clinic’s electronic health record (EHR) system--“Practice Partner.” 
2. Send a survey to those patients identified as current smokers (see Appendix 
A).  Based on return survey results, identify patients willing to participate in 
the program who wished to quit or who were willing to switch from tobacco 
cigarettes to e-cigarettes.   
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3.  Provide each participant with informed consent regarding program to read 
and sign prior to participation (see Appendix B for consent and Appendix K 
for Institutional Review Board approval). 
Pre-intervention Assessment 
 The goal was to obtain pre-intervention assessments of participants to determine 
smoking history, demographics, likelihood to change and be successful, and baseline 
nicotine dose.  The objectives were as follows: 
1. Evaluate participants’ stage of change, smoking status, length of time they 
smoked, number of cigarettes per day, previous attempts to quit, past 
interventions used for smoking cessation, and demographic information 
including age, gender, education level (a former smoker was defined as an 
individual who was actively trying to quit and had not smoked in at least 24 
hours).  
2. Build The Stages of Change questions (see Appendices C and D) into the 
smoking cessation template in Practice Partner EHR and use as the 
framework for this program to assist in evaluating an individual’s readiness 
to quit smoking.  Knowing which stage of change an individual is in was 
thought to help tailor the information and guidance provided to maximize 
success with smoking cessation. 
3. Evaluate nicotine dependence using the revised Fagerstrom nicotine 
tolerance test (FNTT; Heatherton, Kozowski, Frecker, & Fagerstrom, 1991).  
This test was used to determine the baseline nicotine dose for e-cigarettes 




 The goal was the implementation of a structured, systematic smoking cessation 
program using the “Five A’s” model for treating tobacco use and dependence to include 
options to either help smokers quit entirely or switch from tobacco cigarettes to electric 
cigarettes (see Appendix F).  The objectives were as follows: 
1. Develop program by reviewing current literature for best practices in 
smoking cessation related to addiction, frameworks for behavior change, 
nicotine replacement therapies and prescription medications, and patient 
education.   
2. Adopt and adapt selected education materials based on the "5 A's" model 
(see Appendix F) for treating tobacco use and dependence developed by the 
Colorado Collaborative Clinical Guidelines (2004). 
3. Provide staff development and education regarding program details, patient 
data, and Practice Partner EHR prior to implementation.  
4. Discuss options for smoking cessation with each participant at initiation of 
program and allow the participant to choose which cessation method he or 
she would like to try.  Provide written information on different cessation 
options, success rate, risks, and benefits at the initiation of the program (see 
Appendix G).  
5. Provide written information on dangers of smoking and benefits of quitting, 
support, and resources to help with quitting at the initiation of program to 
each participant (Colorado Collaborative Clinical Guidelines, 2004).  
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6. Develop a plan and timeline to decrease nicotine dose based on nicotine 
dependence, personal preference, desire to quit, and health risks for each 
participant and evaluate their nicotine dose during each follow-up phone 
call.   
7. If the participant chooses to try e-cigarettes, provide written information on 
BluCig and SmokeTip e-cigarettes (the two e- brands recommended for this 
program) regarding cost, availability, and nicotine dosage options (see 
Appendices H and I).  
8. Develop and implement a follow-up plan that integrates phone calls or 
office visits for each program participant at two weeks, one month, three 
months, and six months.  Document follow-up data in Practice Partner EHR 
(see Appendix J) that includes evaluation questions regarding smoking 
status, nicotine dosage, e-cigarette likability, usage, and comments. 
Tools Used in Program 
• The five stages of change used as the framework for this project (pre-
contemplation, contemplation, preparation, action, and maintenance) 
provided a structured evidence-based framework to assist in evaluating an 
individual’s readiness to quit smoking and support for the smoking cessation 
process (see Appendix D).  Knowing which stage of change an individual 
was in helped tailor the information and guidance provided to maximize 
success with smoking cessation.  It was used to help predict the individual’s 
success rate at smoking cessation (see Appendices C, D, and F). 
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• The revised Fagerstrom Test for Nicotine Dependence (FTND; Heatherton 
et al., 1991) was used to assess each participant’s degree of physical 
dependence on nicotine.  The Fagerstrom Tolerance Questionnaire (FTQ; 
Fagerstrom, Hughes, Rasmussen, & Callas, 2000) is a 10-item questionnaire 
and the questions are scored on a 5-point Likert scale; the total score is the 
mean rating across all 10 items.  The assumption was the higher the score 
the greater the degree of addiction.  The questions were used to assess the 
degree of urgency an individual felt to restore nicotine levels to a given 
threshold after nighttime abstinence and to evaluate the urge the individual 
had to maintain their nicotine threshold during waking hours.  This test was 
used to evaluate the baseline nicotine dose for NRT or e-cigarette for 
smoking cessation (see Appendix E).  
• Pre-intervention surveys were completed by participants at onset of program 
regarding demographic information, smoking history, previous quit 
attempts, and methods tried. 
• Education material on the effects of smoking and benefits of quitting 
accessed through the Colorado Collaborative Clinical Guidelines (2004) 
were provided to each patient at the initiation of program.  
• Informational material was provided to participants regarding effectiveness, 
cost, and potential side effects of different cessation methods at initiation of 
program.  
• Information on the two chosen e-cigarettes (BluCig and SmokeTip) that 
were used in this program regarding cost, nicotine doses and flavors, and 
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accessibility was provided to participants at initiation of the program (see 
Appendices H and I).  
• Phone calls to participants during implementation and at completion of 
program regarding smoking status, decrease in number of cigarettes if still 
smoking, nicotine level if using e-cigarette, type of e-cigarette they chose, 
and comments regarding e-cigarette likability, usability, durability. 
Program Evaluation Objectives and Design 
The objectives of this capstone project were to evaluate the Kinder Family Clinic 
Smoking Cessation Program using the Donabedian and bridge evaluation models 
regarding its structure, processes, and outcomes (Donabedian, 1972; Sieloff, 1999).  
These theoretical frameworks provided the foundation for evaluating the extent to which 
the program met each specified goal and objective, possible barriers and facilitators, and 
recommendations for future improvements. 
Donabedian Model 
Structural measures evaluated the facility or setting used, human resources 
including qualifications and experience, and the organizational resources including the 
Practice Partner EHR and size of the practice and program. 
Process measures evaluated for this program included the screening, treatment, 
education, and follow-up phone surveys of participants. 
Outcome measures evaluated for this program included participation level, 
demographic data of participants, success rate of participants, e-cigarette data, and 




Bridge Evaluation Model 
By incorporating the bridge evaluation model into the evaluation process, human 
factors critical to an evaluation’s success were also taken into account.  According to 
Sieloff (1999), the bridge evaluation model included the following: 
1. Goal Identification: What is to be evaluated?  What problem is the 
evaluation intended to address?  What is the purpose of the evaluation?  
How can the essential program activities be linked to the goal?  How do 
time and resource factors affect the evaluation goal? 
2. Interpersonal Relationships: Will the interpersonal relationships support the 
efficient and effective implementation of the evaluation plan?  What kind of 
communication might improve the evaluation implementation and reporting 
system?  What kind of bias exists regarding the program being evaluated 
and those who can influence the evaluation design, data, and use? 
3. Ethics: What are the essential program activities and are they legal/ethical?  
How will the type and use of data be collected for the evaluation?  How and 
by whom will the information be used?  What use will the evaluation 
findings serve and is it ethical? 
4. Politics: Why is the evaluation being requested?  Who will participate and 
what are their roles in the evaluation?  What political use will the evaluation 
findings serve, if any?  Who else needs to know about the evaluation 
findings (e.g., stakeholders)?   
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5. Determination: Can the evaluation design meet the evaluation goal given the 
scope and context of the evaluation’s purpose?  Who will use the evaluation 
findings?  How will the determination affect stakeholders?    
Bridge Model Technical Factors 
1. Design: Create an evaluation plan and design the evaluation system in 
accordance with the goals.  This could include criteria and objectives, type 
of evaluation (formative or summative), evaluator, purpose, evaluation 
approach, data-collection requirements-tools-protocol, resources and 
supplies, environmental considerations, and reporting methods. 
2. Collect Data: Gather qualitative or quantitative data in accordance with the 
evaluation plan using methods that achieved the objectives.  This could 
include survey instruments, private interviews, group interviews, previously 
collected related data, and observations including tests and document 
review.  
3. Test/Assess: Synthesize the findings from the qualitative and quantitative 
methods to test the validity, completeness, or correctness of the data.   
4. Report: Prepare the report for the target audience in accordance with the 
evaluation plan to include the introduction, evaluation, conclusions, and 
recommendations.  This might include achievement of evaluation 
objectives, noted violations of ethical principles, alterations in the original 
evaluation needs, value of the evaluation’s accomplishment, the process and 
outcomes of the data assessment, and results achieved via the evaluation 
system.   
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5. Evaluation Results: Perform an evaluation on the effectiveness of the 
evaluation using the model.  
Congruence of Organization’s  
Strategic Plan to Project 
Kinder Family Clinic was completely supportive of this program with the focus 
on improving the health of the community.  The clinic is a private physician-owned 
health care clinic in rural northwest Colorado located in Craig.  Kinder Family Clinic is 
staffed by a Family Nurse Practitioner, Dr. Pamela Kinder, who is a neurologist and the 
owner of the clinic; two receptionists; and two medical assistants.  The clinic seeks to 
expand family practice patients and focus on health promotion and disease prevention 
practices and programs.  The mission statement for Kinder Family Clinic is to provide 
excellent care in a nurturing, welcoming environment to the people of the Yampa Valley.   
The goals of Kinder Family Clinic are (a) to provide quality care for each patient; (b) to 
recognize, respect, and appreciate each team member’s individuality and talents; (c) to 
utilize the skills of each individual; (d) to have more understanding of our patients’ 
needs; to have a safe and healthy working environment; and (e) to make Kinder Family 
Clinic successful.  The visions for the future for the clinic are (a) to work to become 
increasingly recognized as providing the highest quality care available in the profession 
as measured by patient satisfaction and cost effectiveness; (b) to provide leadership in the 
community by actively participating in professional and community groups; and (c) to 
commit to excellence and respond to our patients with a level of care that exceeds their 






 Resources needed to implement program into Kinder Family Practice included the 
following: 
• Patient questionnaire on stages of change, addiction level, baseline nicotine 
dose, and demographic data.  It was provided to each participant to complete 
at initiation of program and was also built into the Smoking Cessation 
Template in Practice Partner (Kinder Family Clinic, 2011). 
• Educational material on effects of smoking and benefits of quitting prepared 
by Colorado Collaborative Clinical Guidelines (2004) were provided to each 
participant at initiation of program. 
• Informational material on all options for smoking cessation including 
effectiveness, cost, and potential side effects provided to each participant at 
initiation of program (see Appendix G). 
• Information on BluCig and SmokeTip e-cigarette regarding cost of kit and 
replacement nicotine cartridges, doses and flavors of nicotine cartridges, and 
where it can be purchased (see Appendices H and I) were provided to each 
participant at initiation of program. 
• Time to send survey, review responses, and contact participants of program.   
Risks 
 No risks were identified related to the use of electric cigarettes compared to 
tobacco cigarettes; the data show them to actually reduce the health related risks seen 





E-cigarettes could become a new option to help with smoking cessation if proven 
to be effective, diminishing or alleviating the risks associated with tobacco cigarettes and 
second-hand smoke.  E-cigarettes are also cheaper than tobacco cigarettes and many of 














The evaluation plan provides a systematic outline of the processes implemented to 
meet the aims of the program evaluation and include the following: 
1. Clear identification of the purpose of the evaluation 
2. Evaluation questions based on program structure, inputs (processes) and 
expected outcomes 
3. Design and methodology to guide data collection and analysis 
4. Recommendations based on the interpretation of the data analysis 
Purpose of the Evaluation 
The purpose of this evaluation was to determine achievement of program goals, 
identify effective program components, determine why some program components were 
effective while others were not, identify potential program improvements, and provide 
information on the program’s cost effectiveness and outcomes.  The Donabedian (1972) 
and bridge (Sieloff, 1999) models were used as a framework to guide the elements of the 
evaluation. 
The following questions guided the program evaluation and were answered 
through collection and analysis of specific data:  
Q1 Were the stated goals and objectives of the program met, not met, or  
 partially met?  
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Each program goal (outlined in Chapter II) was assessed based on appropriate and 






Program Goals and Objectives 
 
Goal Objective 
Recruit patients from Kinder 
Family Clinic Practice and 
the surrounding community 
who were willing to 
participate in the program. 
• Identify Kinder Family Clinic patients who are current smokers using the 
clinic’s EHR system “Practice Partner”. 
• Send a survey to those patients identified as current smokers. (Appendix A).  
Based on return survey results, identify patients who were willing to 
participate in the program who wished to quit, or who were willing to switch 
from tobacco cigarettes to e-cigarettes.   
• Provide each participant with informed consent regarding program to read and 
sign prior to participation. 
 
Obtain pre-intervention 
assessment of participants to 
determine smoking history, 
demographics, likelihood to 
change and be successful, 
and baseline nicotine dose. 
• Evaluate participants’ stage of change, smoking status, length of time they 
smoked, number of cigarettes per day, previous attempts to quit, past 
interventions used for smoking cessation, demographic information including 
age, gender, education level. (A former smoker was defined as an individual 
that was actively trying to quit and had not smoked in at least 24 hours.)  
• Build The Stages of Change questions (Appendix C), into the smoking 
cessation template in Practice Partner EHR, and use as the framework for this 
program to assist in evaluating an individual’s readiness to quit smoking.  
Knowing which stage of change an individual is in was thought to help tailor 
the information and guidance provided to maximize success with smoking 
cessation. 
• Evaluate nicotine dependence using the Fagerstrom Nicotine Tolerance Test 
(FNTT).  (This test was used to determine the baseline nicotine dose for e-
cigarettes for smoking cessation (Appendix E).) 
 
Implementation of a 
structured, systematic 
smoking cessation program 
using the “Five A’s” Treating 
Tobacco Use and 
Dependence to include 
options to either help 
smokers quit entirely or 
switch from tobacco 
cigarettes to electric 
cigarettes (Appendix F). 
 
• Develop program by reviewing current literature for best practices in smoking 
cessation related to addiction, frameworks for behavior change, NRTs and 
prescription medications, and patient education.   
• Adopt and adapt selected education materials based on The "5 A's" model 
(Appendix F), for treating tobacco use and dependence that was developed by 
the Colorado Collaborative Clinical Guidelines (Colorado Collaborative 
Clinical Guidelines, 2004). 
• Provide staff development and education regarding program details, patient 
data, and Practice Partner EHR prior to implementation.  
• Discuss options for smoking cessation with each participant at initiation of 
program, and allow the participant to choose which cessation method he or she 
would like to try. Provide written information on different cessation options, 
success rate, risks, and benefits at the initiation of the program.  
• Provide written information on dangers of smoking and benefits of quitting, 
support, and resources to help with quitting at the initiation of program to each 
participant (Colorado Collaborative Clinical Guidelines, 2004).  
• Develop a plan and timeline to decrease nicotine dose based on nicotine 
dependence, personal preference, desire to quit, and health risks for each 
participant and evaluate their nicotine dose during each follow-up phone call.   
• If the participant chose to try e-cigarettes, provide written information on “blu 
cig” and “smoke tip” e-cigarettes, which were the two e-cigarette brands 
recommended for this program, regarding cost, availability, nicotine dosage 
options.  
• Develop and implement a follow-up plan that integrates phone calls or office 
visits for each program participant at 2 weeks, 1 month, 3 months, and 6 
months.  Document follow-up data in Practice Partner EHR (Appendix H) that 
includes evaluation questions regarding smoking status, nicotine dosage, e-




Q2 Were the structural components (facility/setting, human resources,  
organizatonal resources, EHR, tools) effective and how did they contribute 
to the value of the program?   
 




Evaluate Data Data Collection 
Usefulness of written education on 
smoking cessation. 
1. Packet from Colorado 
Collaborative Guidelines 
2. Smoking Cessation Options 
3. Cost Comparison of NRT 
4. Information on Blu Cig and 
Smoketip E-cigarettes 
 
Subjective Data provided by program 
participants on effectiveness of cessation 
options, cost information, and whether it 
was appropriate and adequate. 
 
Phone interviews to all program participants 
with focused questions regarding feedback 
on program’s educational materials.  
 
 
Electronic Health Records (EHR) 
used for program “Practice 
Partner”. 
Usability and reliability of EHR for data 
collection, management, and analysis 
Determination by primary investigator and 
staff at completion of program, based on 
ability to collect and quantify necessary data 
from EHR. 
Staff education regarding Kinder 
Family Clinic smoking cessation 
program.  
Staff education on program details, patient 
data, and use of EHR for program. 
In person survey of staff  
 
Framework used for program. TTM model (Stages of Change) used to 
evaluate participants readiness to quit 
smoking. 
Stages of Change of participant collected at 
initiation and completion of program. 
Determination/ assessment by primary 
investigator. 
 
Fagerstrom Tolerance Test 
 
Effectiveness, reliability, validity, and 
accuracy of test regarding nicotine 
addiction level of program participants. 
 
Gather and evaluate data from pre-
intervention survey and comments from 
participants during follow up phone calls 




2. Mail Survey 
 
Evaluate information collected on survey 
regarding whether questions appropriate, all 
inclusive, recommended additions, or 
changes.  Mail survey vs. other options for 
communication (emails, text messages, 
website). 
 
Phone interview to participants with focused 
questions.  
Response rate to mail surveys, participant 
and staff opinions and recommendations. 
Phone calls as chosen method of 
contact and follow-up with 
participants. 
 
Phone calls as appropriate and adequate 
communication choice for program.  What 
other methods of communication could 
have been used. 
Response rate of participants to phone calls.  
Participant and staff recommendations 
regarding other options for communication.  
 
Necessary qualifications of 
program administrator/provider. 
Qualifications of primary investigator.  
What other staff could have been used to 
implement this program and necessary 
qualifications 
Determination of primary investigator using 
literature for context regarding needed 
education level to implement and administer 
program.  
 
Program Sustainability and 
Usability. 
 
Recommendations on whether program 
should continue, recommended changes, 
and other potential settings for program. 
Outcome data and cost analysis regarding 
program use, changes, and other settings 




Q3 Were the processes used for the program effective and how did they  
 contribute to the value?  




Evaluate Data Data Collection 
Identify all current smokers at 
Kinder Family Clinic and 
those willing to participate in 
smoking cessation program. 
 
Were all current smokers 
identified and were they all 
sent an invitation to 
participate in smoking 
cessation program using e-
cigarettes. 
 
Use Practice Partner EHR to 
identify current smokers, 
identify those willing to 
participate based upon results 
from return survey. 
Usefulness of The Stages of 
Change and participation in 
program. 
 
Was this particular model 
useful for determining 
participation in program? 
 
Stage of change of 
participants at initiation and 
completion of program.  Was 
the model applicable to the 
study participants and did it 
provide a framework for the 
implementation/ intervention? 
 
Usefulness of determining 
nicotine addiction level of 
participants at initiation and 
completion of program. 
Determine nicotine addiction 
level to determine appropriate 
baseline nicotine dose for e-
cigarette. 
Use the Fagerstrom Tolerance 
Test to determine nicotine 
level, correlation with 
participant self-report. 
 
Phone Call Follow-up 
Response of participants. 
 
Were phone follow ups at 2 
weeks, 1month, 3months, and 
6 months effective and did 
they contribute to the 
participant’s overall success? 
Use EHR and excel 
spreadsheet to evaluate phone 
contact with each participant. 
 
Q4 What were the outcomes of the program and how do they compare with  
 anticipated outcomes and outcomes of other standard practices?  
Table 5 presents how the outcomes of the program were measured and how they 






Evaluate Data Data Collection 
Current smokers that are patients 
at Kinder Family Clinic and 
participants in program. 
Number of current smokers and 
number of participants of 
program. 
Use EHR and excel spreadsheet 
to collect data. 
 
Demographic information of 
participants 
 
Age, gender, ethnicity, race, and 
education level of participants. 
Quantify data gained from pre-
participation survey and EHR. 
E-cigarettes 
1. Smoking cessation rate of 
participants at completion of 
program that had not 
smoked in at least a month. 
2. Participants that switched 
from tobacco cigarettes to e-
cigarettes. 
3. Participants that decreased 
use of tobacco cigarettes to 
at least less than half of 
usage from initiation to 
completion of program by 
using e-cigarettes. 
Cessation rate, and harm 
reduction rate of participants.  
 
Data obtained from phone call 
f/u with participants, use EHR 
and spreadsheet to quantify data. 
Nicotine addiction level of 
participants  
 
Nicotine level of participants at 
initiation and completion of 
program using Fagerstrom 
Tolerance Test. 
Data obtained from pre-
intervention survey and phone 
call follow up with participants, 





Document comments regarding 
e-cigarette satisfaction, 
effectiveness, cost, reliability, 
accessibility, and improvement 
on quality of life. 
Data obtained from phone call 
f/u with participants, use EHR 
and spreadsheet to quantify data. 
 
 Q5 Was the program cost effective?   
 
 The following costs and/or revenue were related to the program: (a) human 
resources or time spent collecting “current smoker status” on Kinder Family Clinic 
patients from Practice Partner EHR; (b) time spent on copying and preparing the 
invitations for mailing; (c) cost of mailing the 640 invitations to Kinder Family Clinic 
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patients identified as current smokers; (d) time spent by the primary investigator 
gathering educational information; (e) time and cost of copying the educational data; (f) 
time spent by primary investigator with each participant completing survey, providing 
educational material, e-cigarette information, and smoking cessation counseling; (g) time 
spent by primary investigator performing follow-up phone calls to each participant at two 
weeks, one month, three months, and six months; (h) projected cost to health care system 
if they kept smoking; and (i) reimbursement for the smoking cessation program clinic 
visits based on payor source. 
Data Collection and Analysis 
Specific tools were used to assess the degree to which each program goal was met 
as well as the specific evaluation questions.  In some cases, standardized tools were used 
while other evaluation questions required survey tools developed specifically for this 
program.  
• An electronic health record system (Practice Partner EHR) was used to 
identify potential participants and collect and maintain patient data/ 
information throughout the program. 
• The main frameworks used for evaluating this program were the 
Donabedian (1972) model and the bridge evaluation model (Sieloff, 1999).   
• The TTM model Five Stages of Change evaluated a participant’s readiness 
to quit. 
• The Fagerstrom Tolerance Test was used to evaluate participants’ nicotine 
addiction level and to recommend baseline nicotine dose.   
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• The participant survey that included questions on demographic information, 
smoking history, previous quit attempts, and methods tried was provided to 
each participant at initiation of program.  
• Education material on the effects of smoking and benefits of quitting was 
accessed through the Colorado Collaborative Clinical Guidelines (2004).  
• Informational materials were provided to participants regarding 
effectiveness, cost, and potential side effects of different cessation methods. 
• Information was provided on the two chosen e-cigarettes (Blu Cig and 
Smoke Tip) used in this program regarding cost, nicotine doses and flavors, 
and accessibility.  
• Phone calls were made to participants during implementation and at 
completion of program regarding smoking status, decrease in number of 
cigarettes if still smoking, nicotine level if using e-cigarette, and comments 
regarding e-cigarette likability, usability, durability. 
Recommendations 
Following systematic analysis of the data, recommendations were developed 
regarding how to continue this program more effectively.  The data interpretation was 
conducted to determine what elements of the program should undergo revisions, 
additions and/or deletion, and what other potential options exist for effective 
implementation (e.g., other settings, use of different types of staff).  Finally, outcome 












Presentation of the results of the program evaluation are organized based on the 
purpose of the evaluation and the five primary evaluation questions as outlined in 
Chapter III: Evaluation Plan.  This results chapter describes the achievement of the 
program goals, effective program components, potential program improvements, cost 
effectiveness, and program outcomes.  The findings are also presented using 
Donabedian’s (1972) model of structure, process, and outcomes.  
Data Analysis and Findings 
 Q1 Were the stated goals of the program met, not met, or partially met?  
 Each program goal (outlined in Chapter II) was assessed based on appropriate and 















Met or Not 
Met 
Recruit patients from 
Kinder Family Clinic 
Practice and the 
surrounding 
community who were 
willing to participate in 
the program. 
Met • Identify Kinder Family Clinic patients who are current smokers using 
the clinic’s EHR system “Practice Partner”. 
• Send a survey to those patients identified as current smokers. 
(Appendix A).  Based on return survey results, identify patients who 
were willing to participate in the program who wished to quit, or who 
were willing to switch from tobacco cigarettes to e-cigarettes.   
• Provide each participant with informed consent regarding program to 
















likelihood to change 
and be successful, and 
baseline nicotine dose. 
Partially 
Met 
• Evaluate participants’ stage of change, smoking status, length of time 
they smoked, number of cigarettes per day, previous attempts to quit, 
past interventions used for smoking cessation, demographic 
information including age, gender, education level. (A former smoker 
was defined as an individual that was actively trying to quit and had 
not smoked in at least 24 hours.)  
• Build The Stages of Change questions (Appendix C & D), into the 
smoking cessation template in Practice Partner EHR, and use as the 
framework for this program to assist in evaluating an individual’s 
readiness to quit smoking.  Knowing which stage of change an 
individual is in was thought to help tailor the information and guidance 
provided to maximize success with smoking cessation. 
• Evaluate nicotine dependence using the Fagerstrom Nicotine Tolerance 
Test (RTQ).  (This test was used to determine the baseline nicotine 









Implementation of a 
structured, systematic 
smoking cessation 
program using the 
“Five A’s” Treating 
Tobacco Use and 
Dependence to include 
options to either help 
smokers quit entirely 
or switch from tobacco 
cigarettes to electric 
cigarettes (Appendix 
E). 
Met • Develop program by reviewing current literature for best practices in 
smoking cessation related to addiction, frameworks for behavior 
change, NRTs and prescription medications, and patient education.   
• Adopt and adapt selected education materials based on The "5 A's" 
model (Appendix E), for treating tobacco use and dependence that was 
developed by the Colorado Collaborative Clinical Guidelines 
(Colorado Collaborative Clinical Guidelines, 2004). 
• Provide staff development and education regarding program details, 
patient data, and Practice Partner EHR prior to implementation.  
• Discuss options for smoking cessation with each participant at 
initiation of program, and allow the participant to choose which 
cessation method he or she would like to try. Provide written 
information on different cessation options, success rate, risks, and 
benefits at the initiation of the program.  
• Provide written information on dangers of smoking and benefits of 
quitting, support, and resources to help with quitting at the initiation of 
program to each participant (Colorado Collaborative Clinical 
Guidelines, 2004).  
• Develop a plan and timeline to decrease nicotine dose based on 
nicotine dependence, personal preference, desire to quit, and health 
risks for each participant and evaluate their nicotine dose during each 
follow-up phone call.   
• If the participant chose to try e-cigarettes, provide written information 
on “blu cig” and “smoke tip” e-cigarettes, which were the two e-
cigarette brands recommended for this program, regarding cost, 
availability, nicotine dosage options.  
• Develop and implement a follow-up plan that integrates phone calls or 
office visits for each program participant at 2 weeks, 1 month, 3 
months, and 6 months.  Document follow-up data in Practice Partner 
EHR (Appendix G) that includes evaluation questions regarding 












 The program was successful in meeting many of the goals and objectives that 
were outlined.  As planned, all 640 identified patients who were current smokers at 
Kinder Family Clinic were sent an invitation to participate in the smoking cessation 
program.  However, of the 640 who were invited to participate, only 48 chose to do so 
and 44 completed the program.  All participants completed the pre-participation survey, 
were provided educational material on smoking cessation and e-cigarettes, were 
evaluated on their stage of change, and were provided the Fagerstrom nicotine tolerance 
questionnaire to determine baseline nicotine dose.  Interviews with staff revealed they 
perceived they were adequately educated regarding details of the program.  The chosen 
method of follow-up contact by phone was not effective as only 10 (21%) of the 
participants were successfully contacted at all four follow-up calls and four (8%) were 
not contacted at all.  The remaining 34 (71%) were successfully contacted at least once.  
The electronic health record platform, Practice Partner, was found to lack the capabilities 
to successfully track multiple patients with multiple data points.  Thus, a separate Excel 
spreadsheet was created to document and track the data for this program.  
Q2  Were the structural components (facility/setting, human resources,  
organizational resources, EHR, tools) effective and how did they 
contribute to the value of the program?   
 
 Table 7 shows whether the structural components were effective and contributed 








Effectiveness and Value of Structural Measures to the Program 
Measure Effectiveness Notes/Value to  the Program 
Usefulness of written 
education on smoking 
cessation. 









The education material on the effects of smoking and benefits of 
quitting provided to all participants which was obtained through the 
Colorado Collaborative Clinical Guidelines was actually found to be 
quite ineffective at increasing success rate of quitting or switching to e-
cigarettes within this participant group (Colorado Collaborative Clinical 
Guidelines, 2004). 
 
At the completion of the program, only two participants stated they had 
called the Colorado Quit Line, one stated “they were a joke”, and the 
other said “they weren’t very helpful and they weren’t supportive of e-
cigarettes so I never called back.”  The Colorado Quit Line is a state 
funded program and does not recognize or support e-cigarettes as 
cessation method.  For this type of program it is thought that the 
information provided by the State of Colorado on tobacco cessation 
would not be the most effective or appropriate regarding the use and 
recommendations for e-cigarettes as a NRT for smoking cessation or 
harm reduction. 
2.   Smoking Cessation 




Effective All 44 participants questioned at the completion of the program 
regarding the informational material provided regarding effectiveness, 
cost, and potential side effects of different cessation methods stated they 
thought it was effective and informative, especially when comparing the 
cost of different NRT (Appendix G).  Ten of the participants 
commented on the cost of the approved NRT vs. e-cigarettes and how 
much cheaper e-cigarettes were. 
 
3.   Information on 
BluCig and 
SmokeTip  
      E-cigarettes 
Partially 
Effective 
Eight participants also stated that the information provided on the two 
chosen e-cigarettes (BluCig and SmokeTip) that were used in this 
program regarding cost, nicotine doses and flavors, and accessibility 
were helpful.  
 
There were multiple comments regarding how much cheaper e-
cigarettes were compared to tobacco cigarettes and several participants 
commented that was a reason to switch in itself.  
 
However, this information should have been much more inclusive 
regarding different brands, nicotine doses, cost, and accessibility of e-
cigarettes.  One of the recommended brands for this program was only 
available through the internet which was thought to decrease its 
usability.  One of the local brands which came highly recommended by 
five of the participants was the “Mystic” e-cigarette, which could be 
found at multiple convenience stores and Walmart.  The cost of the kit 
was approximately $30 (includes three nicotine cartridges, two e-
cigarette batteries, and a wall charger).  The replacement cartridges 
come in three different strengths (1.4 mg, 1.8 mg, and 2.4 mg) and the 
cost is $13/5 cartridges or $20/10 cartridges regardless of nicotine dose. 
The cost savings on these replacement cartridges is equivalent to 
$2.00/pack of cigarettes compared to the average price of $5.00/pack of 
cigarettes, or a $3.00 savings per pack.   Based on this participant 
feedback, the “Mystic” e-cigarette would be recommended due to easy 
availability, and cost savings related to tobacco cigarettes. 
 
 
                                                                  (Table continues) 
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Table 7 Continued   
Measure Effectiveness Notes/Value to  the Program 
Usability and reliability 
of EHR “Practice 
Partner” for data 
collection and analysis. 
Partially 
Effective 
Upon review of Practice Partner EHR, it was found to be easy to use for 
individualized data but the system was not able to adequately or 
accurately track and quantify data regarding multiple patients in a 
reliable way.  
 
An Excel spreadsheet was used at the completion of this program to 
quantify results.  
 
For future program participation within this same setting, or in other 
settings, a better program is recommended that can more accurately 
identify current smokers within the practice and that is able to 




Family Clinic smoking 
cessation program. 
 
Effective Focused questions to staff determined that they felt they were 
adequately informed and educated regarding program 
Usefulness of the TTM 
model Five Stages of 
Change Framework 
used for program. 
Ineffective The TTM model Five Stages of Change that was used to evaluate a 
participant’s readiness to quit, was not found to be an effective tool for 
this program, as all participants were found to be in the “action stage” 
or they would not have participated in the program. 
 
The TTM model could be still be used in a clinic setting to identify 
what stage of change a current smoker is in, and their readiness to quit 
or willingness to even receive cessation information/education.  
 
It could be used along with the “5 A's” to encourage patients to quit 
smoking at each health care visit, but is not recommended as the basis 





reliability, validity, and 
accuracy of to measure 
nicotine addiction level 
of program 
participants. 
Effective The Fagerstrom Tolerance Test was used to evaluate participants’ 
nicotine addiction level and to recommend baseline nicotine dose.  This 
was an excellent tool to use to evaluate addiction level and choose 
appropriate baseline nicotine dose to prevent withdrawal symptoms, 
which is the most common reason to start smoking tobacco cigarettes 
again (Fagerstrom, Hughes, Rasmussen, & Callas, 2000).  
 
This tool was found to be easy to use and understand, applicable, and an 
effective way of determining baseline nicotine levels. The correlation 
between the nicotine level on the FTT and what the participant stated 









The participant questionnaire included questions on demographic 
information, smoking history, previous quit attempts, and cessation 
methods tried. It was found to be an effective method to collect baseline 
data; however, it is recommended that a follow-up questionnaire be 
provided to all participants at the end of the program.   
 
It is also recommended to create multiple or alternative methods of 
communication with participants such as email, website, or text 
messaging, instead of limiting communication to phone or in office 
follow-up.  It is felt this would have improved the participation rate and 
the follow-up contact. 
 
 
                                                           (Table continues) 
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Table 7 Continued   
Measure Effectiveness Notes/Value to  the Program 
Phone calls as chosen 






The follow-up method chosen for this program was found to be a poor 
choice.  It was limited strictly to phone calls at two weeks, one month, 
three months, and six months after each participant started the program.  
The success rate of contact at each planned follow-up was only 10 of 44 
participants or 23%.  However, all but four participants were contacted 
at least once during the program, so overall the successful participation 
was 92%.  Unfortunately, since this program was limited strictly to 
phone contact, two of the four participants that were never contacted, 
had the wrong phone number listed for their contact information.  Had 
there been other methods of contact implemented at the start of the 
program the successful follow-up rate could have been 100%.   
 
The follow-up questions regarding current  smoking status, decrease in 
number of cigarettes if still smoking, nicotine level if using e-cigarette, 
comments regarding e-cigarette likability, usability, durability were 
found to be helpful and appropriate.  However, it is thought that there is 
some other important information that could have been gathered from 
participants’ opinion regarding appropriate frequency of follow-up 
contact, preferred method of contact, preferred duration of the program, 
and recommended support material or advice 
 
Necessary 






The primary investigator for this program was a certified Family Nurse 
Practitioner with 20 years of nursing experience, and 12 years’ 
experience as a nurse practitioner working in a rural setting and treating 
chronic disease, tobacco abuse and its multiple related health problems. 
Although this experience and education was beneficial to the 
development and implementation of the initial program, it is thought 
that this program could be implemented by multiple individuals with 
varying levels of education or experience.   
 
This program could easily be implemented by multiple staff members, 
such as a medical assistant, licensed practical nurse, or even 
receptionist, and overseen by a primary care provider. Once the 
structure is developed for the program, any interested party could 
provide the necessary ongoing education and follow-up.   
  
There could be bias on the side of the primary investigator due to the 
fact that the same individual developed, implemented, and evaluated the 
program.  Steps to remove or limit bias included having a set structure 
to the program, ensuring the same information, questionnaire, and 
educational material was provided to all participants in the same 
manner, and that all names or other identifying information were 




Effective This program could be useful in multiple settings.  Due to the financial 
benefits, and the accessibility of e-cigarettes this program could be used 
in several health care settings such as indigent and urgent care clinics, 
private and specialty clinics, public health facilities, hospitals, and long 
term care facilities.   
 
The fact that, at this time, e-cigarettes can be used in places where 
tobacco cigarettes are prohibited and that they are less than half the cost 
of tobacco cigarettes and other NRT (Appendix G) makes e-cigarettes 
an affordable, accessible, cheaper NRT option.  The main constraint 
that would inhibit the use of e-cigarettes in any government funded 





 Q3 Were the processes used for the program effective and how did they  
  contribute to the value? 
 
 Table 8 indicates the processes used for the program, whether they were effective, 





Effectiveness and Value of Process Measures to the Program 
Measure Effectiveness Notes/Value to the Program 
Identify all current smokers at Kinder 
Family Clinic and those willing to 
participate in smoking cessation program. 
Partially 
Effective 
Kinder Family Clinic 3000 patients: 640 
identified as current smokers and sent 
invitation to participate in program. 
(Equivalent to the national and state average 
at 21% (CDC, 2012). 
 
48 responded to invitation and started 
program (7.5% of smokers (Practice Partner 
Electronic Health Records, 2011). 
44 participants finished program (6.9%.  
Though this participation rate was quite 
dismal, it was higher than the national 
average of 4 % (CDC, 2012).  
 
However, due to misinformation on the part 
of patients, failure to document on the part 
of Kinder Family employees, or failure of 
Practice Partner EHR to accurately track 
this information, it is possible and probable, 
that the actual number of current smokers is 
much higher.   
 
Usefulness of The Stages of Change and 
participation in program. 
 
Ineffective All participants were in action stage in at the 
initiation of the program. 
At completion of program, seven 
participants were still smoking or had 
started smoking so were no longer 
considered to be in the action stage but back 
in the contemplation or pre-contemplation 
stage.   
 
Of the remaining 37 participants 21 of them 
had quit (14) or switched to e-cigarettes (7) 
so were considered to be in the maintenance 
stage.   
The remaining 16 participants had either cut 
down to smoking less than half of where 
they started (3) or had cut down to less than 
half and were using e-cigarettes (13) at the 
completion of the program so were still 
considered to be in the action stage. 
 
Usefulness of determining nicotine 
addiction level of participants at initiation 
and completion of program. 
 
Effective Determining participants” nicotine addiction 
level at the onset of the program was helpful 
in determining their baseline nicotine dose 
for e-cigarette and correlated with their 
successful cessation rate or ability to switch 
to e-cigarettes. 
                            (table continues) 
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Table 8 Continued   
Measure Effectiveness Notes/Value to the Program 
Determine whether all participants 
received educational handouts at initiation 
of program. 
1. Information on effects of smoking and 
benefits of quitting. 
2. Information on NRT options and cost 
comparison.  
3. Information on e-cigarette options, 
cost, availability, nicotine dosage, and 
flavor options.  
 
Effective Through evaluation of EHR documentation 
and participant response it was determined 
100% of participants were provided 
educational material. 
Phone Call Follow-up Response of 
participants.   
Partially 
Effective 
Number of participants contacted all 4 
attempts = 10 (21%) 
Number of participants contacted on 3 
attempts = 11 (23%) 
Number of participants contacted on 2 
attempts = 7 (15%) 
Number of participants contacted on 1 
attempt = 16 (33%) 
Number of participants never contacted = 4 
(8%) 
Total participants contacted at least once 
= 44 (92%) 
 
 Q4  What were the outcomes of the program and how do they compare with  
  anticipated outcomes and outcomes of other standard practices? 
 
Kinder Family Clinic has a patient population of 3,000; of this patient group, 640 
(21%) were identified as current smokers.   Of the 640 current smokers who were sent an 
invitation to participate in the Kinder Family Clinic Smoking Cessation Program, 48 
responded and started the program; 44 (92%) completed the program.  Of the 44 
participants who completed the program, 15 were male and 29 of them female.  All 44 
participants were non-Hispanic/White and ranged in age from 20-75; the largest 
percentile (30%) were in the 51-60 age group and 25 (57%) had a high school education 






Participant Demographics  
 
Participant Male Female Total 
Percentile 
Age    
20-30 3 3 6 
3140 3 5 8 
41-50 4 4 8 
51-60 3 10 13 
61-70 2 5 7 
71 and Over 0 2 2 
Total 15 29 44 
    
Race/Ethnicity    
Non-Hispanic/White 15 29 44 
    
Education Level    
Some High School 2 4 6 
High School Diploma/GED 7 12 19 
Trade School 5 2 7 
Associate’s Degree 1 7 8 
Bachelor’s Degree 0 2 2 
Master’s Degree 1 1 2 
 
 
The participants were provided the Nicotine Tolerance Test (RTQ) at the 
initiation of the program to determine baseline nicotine level.  The participants were 
provided the RTQ at the initiation of the program to determine baseline nicotine level.  
Of the 44 participants who completed the program, 39 (89%) were determined to be at 
either the full strength or light strength nicotine dose.  Upon completion of the program 
six months later, only 23 (52%) participants were still using either the full or light 
nicotine dose and 16 (36%) had decreased down to placebo (0 mg) level (see Tables 10, 





Nicotine Addiction Levels of Participants at Initiation of Program and at Six Months 
Categories of RTQ 
scores (nicotine 
levels) for all 
participants  
N= 44 
# of Participants 




# of Participants 
based on RTQ 
scores 
who did not 
complete  
program 
# of Participants 





Full (16 mg) 22 2 12 
Light (12 mg) 21 2 11 
Ultra Lights (8 mg) 5 0 5 
Placebo ( 0 mg) 0 0 16 
Total 48 4 44 
Note. N = 44. 
 
 Participants who completed the six-month program had either stopped smoking 
tobacco cigarettes and no longer used other cessation interventions, stopped smoking 
tobacco but continued to use either e-cigarettes, or a combination of e-cigarettes and 









Nicotine Levels of Participants Following Completion of Smoking Cessation Program 





Nicotine levels of participants who quit smoking 
tobacco and no longer use e-cigs or medication 
  
Full (16 mg) 7  
Light (12 mg) 4  
Ultra Light (8 mg) 1  
Placebo (0 mg ) 2  
Total 14  
   
Nicotine levels of participants who switched to 
e-cigarettes 
  
Full  6 4 
Light 0 2 
Ultra Light 1 1 
Placebo 0 0 
Total 7 7 
   
Nicotine levels of participants who were using 
both tobacco cigarettes and e-cigarettes 
  
Full  3 2 
Light 9 8 
Ultra Light 1 3 
Placebo 0 0 











































      
BlueCig 5 1 2 0 0 2 
SmokeTip 6 3 1 1 0 1 
Other 15 6 0 4 1 4 
       
E-Cigarette & 
Bupropion 
      
BluCig 2 0 0 0 0 2 
SmokeTip 5 1 1 1 0 2 
Other 9 1 3 1 2 2 
       
E-Cigarette & 
Chantix 
      
Blu Cig 1 1 0 0 0 0 
Smoke Tip 1 1 0 0 0 0 




The use of e-cigarettes for smoking cessation was determined to be a successful 
alternative to other NRT.   Fourteen participants (32%) quit smoking both tobacco and e-
cigarettes and seven (16%) switched to e-cigarettes and were no longer smoking tobacco 
cigarettes.  This indicated a success rate for smoking cessation of  48%f, which was much 
higher than the national average of only 25% (CDC, 2009).  Of the remaining 23 
participants, 13 of those (30%) successfully cut down to less than half of their starting 
tobacco use level with the use of e-cigarettes, thus showing a large decrease in their harm 
reduction level.  Of the 14 participants who quit, 10 used e-cigarettes exclusively, two 
were also using Bupropion and two were also using Chantix.  Of the seven who switched 
to e-cigarettes, three were only using e-cigarettes and four were using e-cigarettes and 
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Bupropion.  Of the 13 participants who cut down to less than half of starting amount of 
tobacco cigarettes, seven were only using e-cigarettes and six were using e-cigarettes and 
Bupropion.   
 Q5  Was the program cost effective? 






Cost Effectiveness of the Smoking Cessation Program 
Measure Actual (Possible) 
Cost 
Reimbursement Notes/Comments 
The human resources or time 
spent collecting “current 
smoker status” on Kinder 
Family Clinic patients from 
Practice Partner EHR. 
 
$22 $0 Done by receptionist ($11/hr x 2 
hours) 
Time spent on copying and 
preparing the invitations for 
mailing. 
 
$33 $0 Done by receptionist ($11/hr x 3 
hours) 
Cost of mailing the 640 
invitations to Kinder Family 
Clinic patients identified as 
current smokers. 
 
$288 $0 640 x .45 = $288 
If invitation sent via text, 
email, or posted on website it 
would have been free. 
 





$0 Primary Investigator ($50/hr x 4 
hours).  This would not need to 
be collected again for 
continuation of program, and 
any updates or additions to 
material could easily and 
effectively be done by ancillary 
staff.  
Medical Assistant ($15/hr x 2 
hours = $30)  
 
Time and cost of copying the 
educational data 
 
$22 $0 Done by receptionist ($11/hr x 2 
hours) 
Time spent by primary 
investigator with each 
participant completing 
survey, providing educational 
material, e-cigarette 







48 x $50 =  $2400 
20 min appointment per 
participant = 16 hrs total/$150 hr 
Primary Investigator ($50 hr x 
16 hours = $800)  
Medical Assistant (Group visit 
x 4 x $15/hr = $60) 
The re-mbursement rate for the 
office visit for Tobacco 
Cessation is approximately $50, 
depending on which commercial 
insurance. 
Group visits would be a much 
more cost effective alternative, 
and could be done by ancillary 
staff. 






Table 13 Continued    
Measure Actual (Possible) 
Cost 
Reimbursement Notes/Comments 
Time spent by primary 
investigator performing 
follow-up phone calls to each 
participant at two weeks, one 
month, three months, and six 
months. 
 
$1600 ($150) $0 Primary Investigator ($50 hr x 
32 hours = $1600)  
Medical Assistant ($15/hr x 10 
hours = $150).  Time spent on 
phone calls, and sending and 
replying to emails, text 
messages, and website. 
Follow-up phone calls could 
have been done by ancillary staff 
making it much more affordable, 
and if alternative methods of 
follow-up (email, website, text 
messages) had been an option 
that would have also make 
program more cost effective.  
 
Total $2965 ($605) $2400 Although the actual costs 
showed a loss of $565 on the 
program, had it been set up 
differently so that ancillary staff 
were responsible for most of the 
participate information, group 
visits vs individual visits, and 
alternative means of 
communication the cost of 
program implementation would 
be much lower and would have 
actually show a profit of $1795 
or more. 
 
Projected cost to health care 
system if they kept smoking 
Hard to  
quantify. 
Hard to  
quantify. 
The actual savings to health care 
system is hard to measure, but 
could be substantial if the death, 
disease, and disability related to 
cigarette smoking were reduced 
by half what the current statistics 
show.  It would also reduce 
deaths and disease related to 




 The following positive comments and recommendations were made regarding e-
cigarette satisfaction, reliability, cost, and improvement to quality of life: 
• “Blu Cig is not the same but effective.  I quit completely using it.” 
 




• “E-cigarettes too heavy, needs to hang from lip more comfortably, but I like the nicotine 
part and feel like I got my nicotine fix okay.”  
 
• “It doesn’t compare to the real thing but it helps relieve nicotine cravings really well.” 
 
• “It really helps when I can’t smoke a regular one and I have cut down to 2-3 regular 
cigarettes a day.” 
 
• “I like the price!  It really helped my breathing and diabetes, makes me want to move 
around more.” 
 
• “Definitely takes craving away and helps if you want to quit.”  
 
• “I think they work when I use them, but I’m not completely quit, down to 2-3 tobacco 
cigarettes/day.”  
 
• “Taste much better than a cigarette! I like the cinnamon as doesn’t remind me of a cigarette, 
but they are much harder to draw, and heavier than I would like.”  
 
• “I decided to just “switch brands” to e-cigarette, still using daily, haven’t had a regular 
cigarette in 3 months and I don’t want one.” 
 
• “I’m down to less than a pack from 2 pack/day using my e-cigarette.  I use it every day and 
really think I can quit completely using it.” 
 
• “I cut down to less than half on tobacco cigarettes using my Blu Cig, still using daily, but I 
don’t like how heavy they are.”  
 
• “I think they work well, but I don’t like how heavy they are.” 
 
 Only three negative comments were given by the participants: “I just didn’t like 
them; I don’t like the taste or the feel of them,” “I hate e-cigs; they don’t taste anything 
like cigarettes,” and “Didn’t help with craving at all.” 
Challenges and Unintended Consequences 
Specific challenges existed related to the practice setting for this program given 
the rural nature and patient demographics.  Most of the participants had a high school 
education or less and many worked at blue collar jobs.  Evidence showed that this group 
had the highest rate of smoking and was the group least likely to quit (CDC, 2012).  The 
specific opportunity related to this program was the small population that chose to 
participate.  Most of the individuals who chose to participate in this program were 
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previously established patients at the health care with a prior established relationship with 
the primary investigator.  This conceivably made them more willing to participate in the 
program, consider smoking cessation options, or at least be willing to try the e-cigarette 













Based on the results of this project evaluation, I strongly recommend this program 
continue in its current setting and be shared with other agencies and institutions.  
Unfortunately, the participation rate was only 7.5% of the 640 Kinder Family Clinic 
patients who were identified as current smokers.  However, 21 (48%) of the 44 
participants either quit or switched to e-cigarettes.  While smoking cessation provides the 
greatest risk reduction, switching to e-cigarettes substantially decreases the risk of 
tobacco related conditions.  Of the remaining 23 participants, 13 had cut down to less 
than half of their previous smoking level and only seven were still smoking the same 
amount at the end of the program as when they started.  This success rate is double both 
the national and state averages of 21 and 24%, respectively (CDC, 2009). 
This program should also be expanded and extended outside the scope of the 
Doctor of Nursing Practice program to increase the success rate of Kinder Family Clinic 
patients for smoking cessation or harm reduction.  The focus should include an ongoing 
evaluation of patients who choose to participate in the program and their continued 
success rate with cessation or harm reduction should be documented at least annually in 




Summary of Evaluation Findings  
and Recommendations 
 The program evaluation resulted in the following recommendations: 
• For future programs within this same setting or in other settings, use a 
different EHR system or data collection program that can more easily and 
accurately identify and track data from multiple participants at multiple 
points.    
• Have multiple staff members involved in the education and counseling of 
participants and the collection of follow-up data.   
• For cost effectiveness, have a primary care provider oversee the program 
and have ancillary staff implement the program.  
• Provide multiple methods of contact to participants including phone, in 
office follow-up, text, email, and website at the initiation of the program and 
follow-up according to participant preference.  
• Find an alternative tool to the TTM for this type of program to encourage 
increased participation.   
• Continue using The Fagerstrom Tolerance Test as a tool to evaluate 
addiction level and choose appropriate baseline nicotine; this tool was 
determined to be reliable, applicable, and an effective way of determining 
baseline nicotine levels. 
• Continue use of a baseline participant questionnaire including questions on 
demographic information, smoking history, previous quit attempts, and 
cessation methods tried; however, standardize the process so the same 
questionnaire is provided to all participants at the end of the program.  It is 
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also recommended that information regarding appropriate frequency of 
follow-up contact, preferred duration of the program, and recommended 
support material or advice be asked of participants. 
•  Find alternative educational material on the effects of smoking and benefits 
of quitting for this type of program; it is not recommended to refer 
participants to the Colorado Quit Line as they do not support the use of e-
cigarettes as a cessation method at this time.  
•  Continue providing informational material regarding the effectiveness, cost, 
and potential side effects of different cessation methods as many 
participants found this information helpful.  It is also recommended to 
continue providing information regarding different brands, nicotine doses, 
cost, and accessibility of e-cigarettes but to include more information on the 
cost and accessibility of local options.     
• Continue the program in its current setting with the above changes and share 
this program with any other agency or institution interested in using e-
cigarettes as a smoking cessation option or a harm reduction method. 
Implications for Practice 
I plan to use the results from this study to continue to improve the health of my 
patients through the use of e-cigarettes as a smoking cessation method or as a “harm 
reduction” method by switching from tobacco cigarettes to e-cigarettes.  I also plan to 
share the results of this project with other clinicians.  The American Association of 
Public Health Physicians, The Department of Community Health Sciences, The 
American Council on Science and Health, and The Tobacco Harm Reduction Research 
57 
 
Committee currently support the use of e-cigarettes for use in smoking cessation.  I 
intend to disseminate my results with those entities and others in the hopes of conducting  
further research on the use of e-cigarettes as a smoking cessation method or as a harm 
reduction method.  
Implications for practice based on the evidence gained from this study could be 
significant.  The e-cigarette completely alleviates the health risks related to second hand 
smoke and dramatically reduces or alleviates the risks to current smokers by removing 
the carcinogens found in tobacco cigarettes.  E-cigarettes are also much cheaper than 
tobacco cigarettes.  A smoker can slowly reduce the amount of nicotine until they are at a 
placebo level, thus reducing or alleviating the symptoms of nicotine withdrawal.  E-
cigarettes provide a new alternative to other NRT options, they are the most like tobacco 
cigarettes in their delivery form, they are the one of the most affordable NRT options 
available, and individuals can use them as a smoking cessation option or as a harm 
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1.  Current Smoker ________ Former Smoker (actively trying to quit, has been at least 
24 hours since last cigarette)______________ 
2. Have you tried to quit?   Yes____ No_____ How Many Times?_______ 
3. What have you tried to help you quit? (Check all that apply) 
Nicotine Patches____________ 
Nicotine Gum ______________ 
Nicotine Lozenges __________ 
Nicotine Nasal Spray ________ 




Electric Cigarettes ___________ 
Other _____________________ 
4.  What method/methods were most successful in helping you quit? __________________ 
_______________________________________________________________________ 
5. Are you interested in trying to quit again? Yes____   No____ 
6. Would you be interested in participating in a study evaluating the above cessation 
options, or would you be interested in switching to an electric cigarette to reduce the 
health risks of the harmful carcinogens found in tobacco cigarettes?  Yes____    No_____    
   
7.  Male_____ Female_____ Age______ Ethnicity:  Hispanic___ Non-
Hispanic____ 
 
Race: White___   African American___ Native American____ Asian/Pacific Islander___   
8. Education Level: (mark highest level) 
Some High School_______________ 
 High School Diploma ____________ 
 Trade School___________________ 
 Associates Degree _______________ 
 Bachelor’s Degree _______________ 
 Master’s Degree _________________ 
























INFORMED CONSENT TO PARTICIPATE  
IN RESEARCH 
 
Identification of Investigators & Purpose of Study   
You are being asked to participate in a research study conducted by Jona Ely, FNP-C at 
Kinder Family Clinic, and Doctor of Nursing Practice student at the University of 
Northern Colorado.  The purpose of this study is to evaluate whether electric cigarettes 
are an effective smoking cessation alternative.  This study will contribute to the 
researcher’s completion of her capstone project and doctoral degree. 
Research Procedures 
Should you decide to participate in this research study, you will be asked to sign this 
consent form once all your questions have been answered to your satisfaction.  This study 
consists of a survey and interviews that will be administered to individual participants at 
Kinder Family Clinic or by phone. You will be asked to provide answers to a series of 
questions related to your previous and present smoking habits, smoking cessation 
options, and interest in quitting.  You will also be provided information on all currently 
approved smoking cessation options plus electric cigarettes.   If you chose a prescription 
alternative you will be provided a prescription and recommendations for follow-up.  You 
may also chose to try more than one cessation option at a time as that has been shown to 
be more effective.     
Time Required 
Participation in this study will require your participation in an initial evaluation, and a 
follow-up phone call or office visit (as deemed appropriate related to your health history 
and needs) at two weeks, one month, three months, six months, and one year. 
Risks  
The investigator does not perceive more than minimal risks from your involvement in 
this study.  Electric cigarettes have not been shown to have any greater health risks than 
tobacco cigarettes.  However, at this time they are not currently approved as a smoking 
cessation option and have not been proven to be safe or effective.  
Benefits 
Potential benefits from participation in this study include complete smoking cessation; or 
a decrease in health related risks by switching to a safer alternative than tobacco 
cigarettes; a financial benefit related to decreased cost of e-cigarettes compared to 
tobacco cigarettes; alleviation of secondhand smoke effects; and convenience of being 
able to use e-cigarette anywhere. 
Confidentiality  
The results of this research will be included in the investigator’s capstone evaluation and 
outcomes.  The results of this project will be coded in such a way that the respondent’s 
identity will not be attached to the final form of this study.  The researcher retains the 
right to use and publish non-identifiable data.  While individual responses are 
confidential, aggregate data will be presented representing averages or generalizations 
about the responses as a whole.  All data will be stored in a secure location accessible 
only to the researcher.  Upon completion of the study, all information that matches up 
individual respondents with their answers will remain in the patient’s electronic health 
record at Kinder Family Clinic. 
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Participation & Withdrawal  
Your participation is entirely voluntary.  You are free to choose not to participate.  
Should you choose to participate, you can withdraw at any time without consequences of 
any kind. 
Questions about the Study 
If you have questions or concerns during the time of your participation in this study, or 
after its completion, or you would like to receive a copy of the final aggregate results of 
this study, please contact: 
 Jona Ely, FNP-C  
 Kinder Family Clinic 
Phone: (970) 826-0911 
Email: kinderfamilyclinic@yahoo.com 
Giving of Consent 
I have read this consent form and I understand what is being requested of me as a 
participant in this study.  I freely consent to participate.  I have been given satisfactory 
answers to my questions.  The investigator provided me with a copy of this form.  I 
certify that I am at least 18 years of age. 
 
 
______________________________________     
Name of Participant (Printed) 
 
 
______________________________________    ______________ 
Name of Participant (Signed)                                   Date 
 
 
______________________________________    ______________ 
















MEASURING CHANGE PROCESSES 
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 MEASURING CHANGE PROCESSES 
 
Forty Core Items Measuring Ten Change Processes With Varimax-Rotated Component Loadings From Two Samples 
Item  
Consciousness Raising 
1 recall articles dealing with the problem of quitting smoking. 
I think about information from articles and advertisements on how to stop smoking. 
1 recall information people had given me on how to stop smoking. 
I recall information people had personally given me on the benefits of quitting smoking. 
Self-Liberation 
I tell myself can choose to smoke or not. 
I tell myself am able to quit smoking if I want to. 
I tell myself that if I try hard enough I can keep from smoking. 
I make commitments not to smoke. 
Dramatic Relief 
Warnings about health hazards of smoking move me emotionally. 
Dramatic portrayals of the evils of smoking affect me emotionally. 
I react emotionally to warnings about smoking cigarettes. 
Remembering studies about illnesses caused by smoking upset me. 
Environmental Reevaluation 
I am considering the belief that people quitting smoking will help to improve the world. 
I stop to think that smoking is polluting the environment. 
I consider the view that smoking can be harmful to the environment. 
I am considering the idea that the world could be a better place without my smoking. 
Helping Relationship 
Special people in my life accept me the same whether I smoke or not. 
I can be open with at least one special person about my experience with smoking. 
I have someone who listens when I need to talk about my smoking. 
I have someone whom I can count on when I'm having problems with smoking. 
Stimulus Control 
I remove things from my home that remind me of smoking. 
I keep things around my place of work that remind me not to smoke. 
I remove things from my place of work that remind me of smoking. 
I put things around my home that remind me not to smoke. 
Counterconditioning 
Instead of smoking, I engage in some physical activity. 
I find that doing other things with my hands is a good substitute for smoking. 
When I am tempted to smoke, I think about something else. 
I do something else instead of smoking when I need to relax or deal with tension. 
Social Liberation 
I see "No Smoking" signs in public buildings. 
I notice that public places have sections set aside for smoking. 
I find society changing in ways that make it easier for the nonsmoker. 
I notice that nonsmokers are asserting their rights. 
Self-Reevaluation 
My dependency on cigarettes makes me feel disappointment in myself. 
I get upset when I think about my smoking. 
I reassess the fact that being content with myself includes changing the smoking habit. 
I consciously struggle with the issue that smoking contradicts my view of myself as a caring and responsible person. 
Reinforcement Management 
I can expect to be rewarded by others if 1 don't smoke. 
I am rewarded by others if I don't smoke. 
Other people in my daily life try to make me feel good when I don't smoke. 


















THE STAGES OF CHANGE MODEL AND CHANGING 






STAGES OF CHANGE MODEL 
 
 
Stage in transtheoretical 
model of change  
 
Patient stage  
 
Incorporating other 
explanatory/treatment models  
 
Precontemplation Not thinking about change 
May be resigned 
Feeling of no control 
Denial: does not believe it 
applies to self  
Believes consequences are not 
serious 
Locus of Control 
Health Belief Model 
Motivational interviewing 
Contemplation Weighing benefits and costs of 
behavior, proposed change 
Health Belief Model 
Motivational interviewing 
Preparation Experimenting with small 
changes 
Cognitive-behavioral therapy 








Relapse Experiencing normal part of 
process of change 




Information from Prochaska, J.O., DiClemente, C. C., & Norcross, J. C. (1992).  In search of 
how people change. American Psychology; 47, 1102-1104, and Miller, W. R, & Rollnick, S. 
(1991). Motivational interviewing: Preparing people to change addictive behavior. New 
York: Guilford. 
 
PROCESSES OF CHANGE 
Process of change       Description 
Consciousness raising      Learning about the problem behavior 
Self‐reevaluation    Determining how one thinks about oneself with 
respect to the problem behavior 
Self‐liberation       Making a commitment to act 
Counterconditioning  Substituting alternative behaviors for the problem 
behavior 
Stimulus control       Avoiding the problem behavior 
Reinforcement management      Rewarding oneself 
Helping relationships  Talking about the problem with people who care 
Dramatic relief       Expressing feelings about the problems 
Environmental re‐evaluation      Environmental support for changing problem 
behaviors 





CHANGING BEHAVIOR FOR YOUR HEALTH 
 
1. On the line below, mark where you are now on this line that measures change in behavior. Are you not prepared to 
change, already changing or someplace in the middle?  
Not prepared to change                                                                                     Already changing 
 
 
2. Answer the questions below that apply to you.  
• If your mark is on the left side of the line: 
How will you know when it's time to think about changing? 
What signals will tell you to start thinking about changing? 
What qualities in yourself are important to you? 
What connection is there between those qualities and "not considering a change"? 
• If your mark is somewhere in the middle: 
Why did you put your mark there and not further to the left? 
What might make you put your mark a little further to the right? 
What are the good things about the way you're currently trying to change? 
What are the not-so-good things? 
What would be the good result of changing? 
What are the barriers to changing? 
• If your mark is on the right side of the line: 
Pick one of the barriers to change and list some things that could help you overcome this barrier. 
Pick one of those things that could help and decide to do it by _______________________ (write in a 
specific date). 
• If you've taken a serious step in making a change: 
What made you decide on that particular step? 
What has worked in taking this step? 
What helped it work? 
What could help it work even better? 
What else would help? 
Can you break that helpful step down into smaller pieces? 
Pick one of those pieces and decide to do it by _______________________ (write in a specific date). 
• If you're changing and trying to maintain that change: 
Congratulations! What's helping you? 
What else would help? 
What are your high-risk situations? 
• If you've "fallen off the wagon": 
What worked for a while? 
Don't kick yourself--long-term change almost always takes a few cycles. 
What did you learn from the experience that will help you when you give it another try? 
3. The following are stages people go through in making important changes in their health behaviors. All the stages are 
important. We learn from each stage.  
We go from "not thinking about it" to "weighing the pros and cons" to "making little changes and figuring out how to 
deal with the  
real hard parts" to "doing it!" to "making it part of our lives." 
Many people "fall off the wagon" and go through all the stages several times before the change really lasts. 
The Readiness to Change Ruler can be used with patients contemplating any desirable behavior, such as smoking 
cessation, losing weight, exercise or substance-abuse cessation. 























The Revised Tolerance Questionnaire (RTQ) 
 
1. How many cigarettes a day do you smoke? (circle one) 
10 or less 11-15   16-20   21-25   26 or more 
 
2. How deeply do you inhale? (circle one) 
1   2   3   4   5 
I do not    Moderately   Very Deeply 
Inhale      
 
3. How often do you smoke more in the morning than during the rest of day? (circle one) 
1   2   3   4   5 




4. How often do you smoke your first cigarette of the day within 30 minutes of waking? (circle one) 
1   2   3   4   5 




5. How difficult would it be for you to give up your usual first cigarette of the day? (circle one) 
1   2   3   4   5 
Not     Somewhat    Extremely 
Difficult     Difficult     Difficult 
 
 
6. How difficult do you find it to refrain from smoking in places where it is forbidden (e.g., in church, at 
the library, cinema, etc.)? (circle one) 
1   2   3   4   5 
Not     Somewhat    Extremely 
Difficult     Difficult     Difficult 
 
7. How often do you smoke when you are sick with a cold, the flu, or are so ill that you are in bed most of 
the day? (circle one) 
1   2   3   4   5 




8. On average, about how much of each cigarette do you smoke? (circle one) 
1/3 or less ½  2/3  ¾  ALL 
 
9. On average, how often do you inhale? (circle one) 
1   2   3   4   5 
Never     About     Always 
Half the     
Time 
 
10. On average, how often do you hold cigarette smoke in your lungs for a moment or two before 
exhaling? 
1   2   3   4   5 
Never     About     Always 
Half the    
Time 
 
Scoring: All items are scored on a 5-point Likert scale. The total RQT score is the mean rating across all 10 items. The 
















THE “5 A’s” MODEL FOR TREATING TOBACCO  




THE “5 A’s” MODEL FOR TREATING TOBACCO USE  
AND DEPENDENCE 
 
Ask about tobacco use Identify and document tobacco use status of every 
patient at every visit. 
Advise to quit in a clear, strong and personalized manner urge 
every tobacco user to quit. 
Assess For current tobacco user, is the tobacco user 
willing to make a quit attempt at this time? 
For the ex-tobacco user, how recent did you quit 
and are there any challenges to remaining 
abstinent? 
Assist For the patient willing to make a quit attempt, 
offer medication and provide or refer for 
counseling or additional behavioral treatment to 
help the patient quit. 
For patients unwilling to quit at this time, provide 
motivational interventions designed to increase 
future quit attempts. 
For the recent quitter and any with remaining 
challenges, provide relapse prevention 














































Blu cigs is the hip electronic cigarette brand. All flavors are exclusively made in the USA by Johnson Creek 
in their FDA registered facility. The new Premium pack adds better functionality, improved performance 
and additional technology to enhance the social and individuality aspect of electronic smoke. The starter 
kit price for blu cigs is $69.95 - $79.95. We recommend buying a starter kit with 2 batteries or more. This 
"2 piece" electronic cigarette model comes with atomizer and cartridge combined called cartomizer. 
 Visit site to buy  
Starter Kit 













Rating Trend: (up) 
Based on 270 user reviews.  
Coupon / 
Promotion 
Code:    
Currently blu cigs does not 
offer any general coupon or 
discount codes like 10% off. 





 Get FREE 
Shipping  
Price per 









LED Color: blue 
blu cigs 
Warranty: 1 year 
 
 
   
 
blu cigs Starter Kit  
Blu's smoke juice flavors are 
made in the USA!  
blu cigs Flavors 
Tobacco, Menthol, 
Cherry, Java, Vanilla  
Nicotine Levels 
Full 16mg, Light 
12mg, Ultra Light 
8mg, Zero: 0mg  
Misc. Info 
* Blue tip 
* USA Made Smoke 
Juice 
* Pack recharges 
batteries and holds 
cartridges. 
* Smallest and 




blu cigs Electronic Cigarette Details 
What are Blu Cigs? Blu Cigs are the latest in Electronic smoking. The blu cigarette pack offers the 
unique ability to charge on the go (blu cig PPC)! Blu Cig is all about giving you the freedom to 
smoke anywhere without tobacco and tar!  
Blu cigs starter kit includes: 
 
* 1 pack to hold 5 cartridges/cartomizers and charges your batteries on the go! 
* 2 electronic cigarette batteries 
* 1 wall charger & 1 USB charger 
* 5-pack of flavor cartridges in the flavor and strength of your choice 
* 30 day money back guarantee and a one year warranty 
 
Advanced Features of the Premium Pack  
• New, patented Social feature  
• No screw charging with battery management system that continually  monitors and 
charges the spare battery  
• Easy charge icons located on the side so you can see the battery level and charging 
progress of the pack and spare battery at any time  

















SMOKE TIP ELECTRONIC CIGARETTE 
SmokeTip delivers the easiest drag system - almost effortless. Replacement cartridges deliver over 250 puffs per 
unit. The starter kit price for SmokeTip is $59.95. We recommend to buy a starter kit with 2 batteries or more. This 


















Rating Trend: (unchanged) 
Based on 214 user reviews.  
Coupon / 
Promotion 
Code:    




Shipping:  Get FREE Shipping  
Price per 

















   
 














Full Flavor, Light, 
Ultra Light, No 
Nicotine  
Misc. Info 
Great product at low 
price  
 
SmokeTip Electronic Cigarette Details 
SmokeTip works like traditional cigarette smoking. It delivers the enjoyment of smoking (the touch and taste) 
without the harmful 2000+ chemicals or problems caused by tobacco smoke. The exciting new SmokeTip product 
design is the key to making this happen. There is no flame with SmokeTip: the small electronic cigarette includes a 
rechargeable battery and replaceable cartridges that provide the smoking experience, without tobacco! Inhaling on 
the SmokeTip gives all the same sensations of smoking. However, the unit releases only simulated smoke (vapor 
mist), that evaporates in the air.  
For any reason, at any time, under any circumstance if your SmokeTip battery stops working you get a free 

































































Statement of Mutual Agreement 
University of Northern Colorado  
DNP Capstone Project  
To Evaluate a Rural Smoking Cessation Program that used Electric Cigarettes as a 
Cessation Method or for Harm Reduction 
Jona Ely 
April 2012 
 Kinder Family Clinic is a private physician owned health care clinic in rural 
Northwest Colorado.  The clinic is a family oriented service and provides care to all ages 
of patients. Most of the individuals in the area have a high school education or less and 
most work at blue collar jobs.  There is evidence to show that this group has the highest 
rate of smoking and is the group least likely to quit.   
The goal of this project is to evaluate an already existing structured smoking 
cessation program focused on patient assessment, education, and routinely scheduled 
follow up in a primary care setting.  The purpose of this project is to evaluate this 
programs tools, methods, data, and structure to determine whether it was effective in 
helping individuals stop smoking or stop using tobacco cigarettes if they are not 
interested in quitting.  
 As both a University of Northern Colorado student and an employee of Kinder 
Family Clinic, the author will have access to confidential records of patients evaluated.  
Strict confidentiality will be maintained at all times and no patient identifying 
information will appear in any printed materials produced or communication of any kind.  
Only information regarding how the evaluation process is conducted, statistical data 
regarding patient demographics, smoking history, past interventions / treatments used for 
smoking cessation, and cessation success will appear.     
The DNP Capstone Project will include a final report and abstract along with 
potential publication in an appropriate professional journal and oral presentation.  Kinder 
Family Clinic will retain property rights to any information containing its name.  As 
community member on the Capstone Committee Dr. Pamela Kinder will agree to 
participate in the review and approval of both the proposal and final version of the project 
and be present by phone for both defense meetings.  Any written and oral communication 
regarding the project will be done with the permission of University of Northern 
Colorado representative Dr. Catherine Dingley, Capstone Committee Chair.  
Signatures: 
_______________________________________________________________________ 
Dr. Catherine Dingley, Capstone Committee Chair 
_______________________________________________________________________ 
Dr. Rhonda Squires  
_______________________________________________________________________ 
Dr. Pamela Kinder, M. D., Owner of Kinder Family Clinic 
_______________________________________________________________________ 
Jona Ely, DNP Candidate 
